Macromolecule Transduction Domain Peptides for Cell Permeability

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current delivery systems for macromolecules like DNA, RNA, proteins, and peptides face challenges such as poor penetration into tissues or cells, toxicity due to non-specific targeting, and degradation, leading to inadequate delivery and side effects.

Innovation Solution

Development of novel macromolecule transduction domain (MTD) peptides with a specific amino acid sequence (SEQ ID NO: 173) that facilitate the transport of biologically active molecules across cell membranes, enabling efficient delivery through cell permeability and minimizing toxicity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional delivery systems are used to deliver macromolecules, then delivery can be achieved, but penetration into tissue or cell is poor

Engineering Contradiction:
Improvedelivery efficiencyVSAvoidpenetration capability
Core Design Contradiction:
ReliabilityVSEase of operation

Solution Approach 1:

The patent uses cell-penetrating peptides (CPPs) as intermediary carriers to facilitate the transport of macromolecules across the plasma membrane. These peptides act as mediators that enable the delivery of cargo molecules (proteins, peptides, oligonucleotides) that would otherwise be unable to penetrate the membrane, thereby resolving the contradiction between delivery reliability and penetration capability

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

The invention creates composite structures by fusing cargo molecules with cell-penetrating peptide sequences. This composite approach combines the membrane-penetration capability of CPPs with the therapeutic function of the cargo, enabling both penetration and reliable delivery of macromolecules to target cells

Inventive Principle:
Principle #40Composite materials

2Quantity of substance

If high concentration is used to achieve adequate local concentration at target, then delivery amount increases, but toxicity and side effects increase

Engineering Contradiction:
Improvelocal concentration at targetVSAvoidtoxicity and side effects
Core Design Contradiction:
Quantity of substanceVSObject-affected harmful factors

Solution Approach 1:

The patent employs cell-penetrating peptides with specific sequences (such as penetratin, Tat peptide, transportan, VP22) that provide targeted cell penetration capability. This allows the delivery system to concentrate the therapeutic effect locally at the target cell membrane and interior, while minimizing exposure and toxic effects in non-target tissues, thereby achieving adequate local concentration without proportional increase in systemic toxicity

Inventive Principle:
Principle #3Local quality

3Quantity of substance

If macromolecules are delivered systemically, then delivery coverage increases, but non-specific targeting causes toxicity

Engineering Contradiction:
Improvedelivery coverageVSAvoidnon-specific targeting toxicity
Core Design Contradiction:
Quantity of substanceVSObject-generated harmful factors

Solution Approach 1:

The cell-penetrating peptides serve as selective intermediaries that facilitate macromolecule delivery specifically at target cells. The peptides' ability to interact with cell membranes and facilitate internalization provides a degree of targeting specificity, reducing non-specific uptake in non-target tissues and thereby minimizing toxicity while maintaining broad delivery coverage

Inventive Principle:
Principle #24Intermediary (Mediator)

4Productivity

If currently known delivery systems are used, then some cellular uptake can be achieved, but efficiency is limited and toxicity remains

Engineering Contradiction:
Improvecellular uptake efficiencyVSAvoidtoxicity
Core Design Contradiction:
ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent systematically varies parameters of the cell-penetrating peptide sequences (amino acid composition, length, charge distribution, hydrophobicity) to optimize both cellular uptake efficiency and reduce toxicity. By adjusting these parameters, the invention achieves enhanced productivity in macromolecule delivery while minimizing harmful effects through rational peptide design

Inventive Principle:
Principle #35Parameter changes

Data Source

PatentEP2837636B1Novel macromolecule transduction domains and methods for identification and uses thereof
Publication Date: 2018.04.11 PROCELL THERAPEUTICS
  • EP2837636B1 patent drawingFigure 1a
  • EP2837636B1 patent drawingFigure 1a
  • EP2837636B1 patent drawingFigure 1a

AI summary

The present invention discloses novel macromolecule transduction domain (MTD) peptides which facilitate the traverse of a biologically active molecule across the cell membrane. Also disclosed are polynucleotides encoding the MTD peptides, methods of identifying the MTD peptides; methods of genetically engineering a biologically active molecule to have cell permeability by using the MTD peptides, methods of importing a biologically active molecule into a cell by using the MTD peptides, and uses thereof.